Why is compounded semaglutide so much cheaper than Wegovy?

The $1,000+ gap between Wegovy’s list price and a $250 compounded program decomposes into: 1. Patent pricing power. Novo Nordisk and Lilly hold patents and price accordingly — U.S. brand prices run several times European prices for identical pens. The brand premium is mostly market structure, not manufacturing cost; the peptide itself is no longer exotic to synthesize. 2. The middleman stack. List prices carry the rebate machinery of PBMs and insurers. Cash compounding routes around the entire apparatus — pharmacy buys API from (ideally FDA-registered) suppliers, prepares doses, ships. 3. No trials to amortize, no Super Bowl ads. Brand prices recoup billions in R&D and marketing; compounders free-ride on the published science. (This is also the fair criticism of compounding economics — innovation has to get paid for somewhere.) 4. Form factor: vials and syringes cost less than precision auto-injector pens. Lilly proved the point itself — LillyDirect’s brand vials undercut its own pens by hundreds. What the discount does and doesn’t buy: at a licensed 503A/503B pharmacy, you’re getting real semaglutide in a formulation FDA hasn’t reviewed, with quality resting on the pharmacy’s license and practices instead of factory QC. That’s a real but bounded trade-off. The unbounded version is mistaking gray-market “research peptide” vendors for compounding — that $99 vial skipped the pharmacy, the prescription, and frequently the semaglutide (how to tell). Sanity-check pricing instinct: legitimate compounded programs (, NexLife, and peers) cluster at $199–$450/month with prescriber screening included. Far below that range, ask what’s been removed — it’s usually the medicine, the doctor, or both.